Sort
40,608 grants matching “prostate cancer”
In Vivo Oncogene-Induced Tumorigenesis and Escape
$370,903Lewis A Chodosh · University Of Pennsylvania · R01 · FY2019 · CA
Prostate Cancer Studies
$370,871Demetrius Albanes · Division Of Cancer Epidemiology And Genetics · ZIA · FY2023 · CA
SENP:Conformational Dynamics and Inhibition by Small Molecules
$370,860Yuan Chen · Beckman Research Institute/City Of Hope · R01 · FY2013 · GM
A Health IT based Psychoeducational Intervention for African American Prostate Cancer
$370,858Brian M. Rivers · Morehouse School Of Medicine · R01 · FY2015 · MD
CHEMOPREVENTION OF PROSTATE CANCER INITIATION IN A NOVEL TRANSGENIC MOUSE MODEL BY TARGETING 15-LIPOXYGENASE-1
$370,831Savannah Health Services, Llc · · FY2008 · Department of Defense
Statistical Methods for Prospective Evaluation of Biomarkers
$370,827Yingye Zheng · Fred Hutchinson Cancer Research Center · R01 · FY2020 · CA
The Role of Fgf Signaling in Vertebrate Development
$370,767Mark Lewandoski · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Role of BMP and FGF signaling during limb development
$370,767Mark B Lewandoski · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Live Tumor Culture Core and Tissue Specific Culture (TSC) System for Human Cancers
$370,748Tan A. Ince · University Of Miami School Of Medicine · R33 · FY2019 · CA
FACILITATING DISCOVERY THROUGH A HUMAN PROSTATE TISSUE R
$370,721University Of Illinois At Chicago · U01 · FY2004 · CA
Informed Decision Making Regarding PSA Screening
$370,708Roshan Bastani · University Of California Los Angeles · R01 · FY2007 · CA
Epigenetic Reprogramming of AR Function in CRPC
$370,667Myles A Brown · Beth Israel Deaconess Medical Center · P01 · FY2015 · CA
Project 4: Identification of Essential Genes Underlying AR Activity in Antagonist-Resistant CRPC
$370,664Myles A Brown · Beth Israel Deaconess Medical Center · P01 · FY2023 · CA
Image-guided IMRT and Brachytherapy for Pelvic Tumors
$370,651Jeffrey F Williamson · Virginia Commonwealth University · P01 · FY2009 · CA
Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancer
$370,628Xiaolin Zi · University Of California-Irvine · R01 · FY2022 · CA
Roles of EAF2 in androgen action in the prostate
$370,620Zhou Wang · University Of Pittsburgh At Pittsburgh · R01 · FY2014 · CA
Role of Nuclear Pore-Regulated Mechanisms in Prostate Cancer Aggressiveness
$370,612Veronica Rodriguez-Bravo · Mayo Clinic Rochester · R01 · FY2024 · CA
Non Invasive Biomarkers for Diagnosing Clinically Significant Prostate Cancer
$370,588Peter S Nelson · Fred Hutchinson Cancer Research Center · R01 · FY2014 · CA
The aberrant androgen receptor underlies abiraterone/enzalutamide resistance
$370,575Jun Luo · Johns Hopkins University · R01 · FY2017 · CA
The aberrant androgen receptor underlies abiraterone/enzalutamide resistance
$370,575Jun Luo · Johns Hopkins University · R01 · FY2016 · CA
Targeting m6A RNA epigenetics in treatment-emergent neuroendocrine prostate cancer
$370,575Min Sup Song · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Cis-aconitate decarboxylase (ACOD1) in PMN-MDSC and prostate cancer progression
$370,575Guocan Wang · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Cis-aconitate decarboxylase (ACOD1) in PMN-MDSC and prostate cancer progression
$370,575Guocan Wang · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Studies of the Antifungal Drug Itraconazole As A Novel Inhibitor of Angiogenesis
$370,575Jun O. Liu · Johns Hopkins University · R01 · FY2017 · CA
The aberrant androgen receptor underlies abiraterone/enzalutamide resistance
$370,575Jun Luo · Johns Hopkins University · R01 · FY2015 · CA